Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 5/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 11/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102888 | 0.87 | GSK3B (0.50) | PIK3C3AURKAAURKBIGF1RITK | |
| SCHEMBL19833663 | 0.79 | PIK3C3 (0.49) | PIK3C3AURKAAURKBIGF1RITK | |
| SCHEMBL343410 | 0.76 | PAK4 (0.54) | PIK3C3AURKAAURKBIGF1RITK | |
| SCHEMBL18297024 | 0.76 | PIK3C3 (0.47) | PIK3C3AURKAAURKBIGF1RITK | |
| SCHEMBL19364254 | 0.76 | NOS3 (0.50) | PIK3C3AURKAAURKBIGF1RITK | |
| SCHEMBL10452895 | 0.75 | BPTF (0.57) | — | |
| SCHEMBL15722709 | 0.74 | AURKA (0.56) | PIK3C3AURKAAURKBIGF1RITK | |
| SCHEMBL18297007 | 0.74 | AURKA (0.50) | PIK3C3AURKAAURKB | |
| SCHEMBL4116079 | 0.74 | PAK4 (0.48) | PIK3C3AURKAAURKBIGF1RITK | |
| SCHEMBL63682 | 0.72 | AURKA (0.46) | PIK3C3AURKAAURKBIGF1RRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140141099-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-05-22 | — | — | US | disclosed |
| US-20140141099-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141099-A1 | DRUG DISCOVERY METHODS | AURKB, AURKC, AURKA | PIK3C3 898/4885AURKA 3/4885AURKB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.